OSE IMMUNO - BUY | EUR17 (+71%) R&D day highlights the ongoing progress on the clinical and preclinical sides
OSE IMMUNO - BUY | EUR17 (+71%)R&D day highlights the ongoing progress on the clinical and preclinical sides
KOL underlined favourable benefit/risk profile of Tedopi in NSCLC
Combination studies for Tedopi
We remind that antigens, included in the Tedopi’s design (such as MAGE2, MAGE3, CEA, HER2/neu, and P53 with a PADRE), are among broadly expressed tumour-associated antigens. For instance, ovarian cancers express MAGE-A2, MAGE-A3 and PRAME as well. Therefore, Tedopi could potentially be applied in different solid tumours. As we discussed previously, if positive, we believe that clinical updates from the combination studies could strengthen Tedopi’s profile for potential in-licensing partner.
Highlighting advantages of targeting SIRPα
Preclinical pipeline focus
Ose Immunotherapeutics SA, formerly Orphan Synergy Europe Pharma SA, is a France-based company principally engaged in the clinical stage biotechnological sector. The Company develops immunotherapy products against invasive or metastatic late-stage cancers. The Company offers a technology, called Memopi, which helps the immune system to eliminate malignant cells; it re-educates the body's immunological memory so that the immune system (and particularly T cytotoxic cells) attacks tumor cells by increasing the patient's specific cytotoxic T response against their cancer. The Company's main product, Texopi, is a patented combination of ten epitopes, selected and optimized from five tumor associated antigens.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.